title: Estimation of psycholeptic and psychoanaleptic medicine use in an adult general population sample using the Anatomical Therapeutic Chemical classification.
abstract: Little is known about psycholeptic and psychoanaleptic medicine (PM) use in the general population. This study presents prevalence data about PM use. The sample included 4310 individuals aged 20-79 from a general population health examination in a northern German area (participation proportion: 68.8%; Study of Health in Pomerania, SHIP). Medicines taken during the past seven days were assessed from the medicine packages or self-reports and classified according to the Anatomical Therapeutic Chemical (ATC) classification developed by the World Health Organization. In total, 6.3% of the sample reported PM intake, 8.7% of the women and 4.7% of the men. During the past 12 months prior to the health examination, 49.2% of the individuals with PM use consulted a general practitioner but not a neurologist or a psychiatrist. Among the study participants with PM use, 88.8% had one or more mental disorders during lifetime according to a screening questionnaire. It is concluded that considerable proportions of individuals with current PM use exist although lower than may be expected on the basis of the number of individuals with mental disorder in the general population.
authors.affiliation: Medical Faculty, Institute of Epidemiology and Social Medicine, University of Greifswald, Greifswald, Germany. ujohn@uni-greifswald.de
authors.forename: U
authors.initials: U
authors.lastname: John
authors.forename: S E
authors.initials: SE
authors.lastname: Baumeister
authors.forename: H
authors.initials: H
authors.lastname: Völzke
authors.forename: H J
authors.initials: HJ
authors.lastname: Grabe
authors.forename: H J
authors.initials: HJ
authors.lastname: Freyberger
authors.forename: D
authors.initials: D
authors.lastname: Alte
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D004363:Drug Utilization / Q000706:statistics & numerical data; D005194:Family Practice / Q000706:statistics & numerical data; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data*; D001523:Mental Disorders / Q000188:drug therapy / Q000453:epidemiology; D008875:Middle Aged; D009462:Neurology / Q000706:statistics & numerical data; D011570:Psychiatry / Q000706:statistics & numerical data; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012017:Referral and Consultation / Q000706:statistics & numerical data; D014600:Utilization Review; D055815:Young Adult
chemical_list: D000697:Central Nervous System Stimulants; D011619:Psychotropic Drugs
references.citation: Int J Epidemiol. 2001 Oct;30 Suppl 1:S35-40
references.pmid: 11759849
references.citation: Br J Clin Pharmacol. 2005 Sep;60(3):306-10
references.pmid: 16120070
references.citation: Acta Psychiatr Scand Suppl. 2004;(420):55-64
references.pmid: 15128388
references.citation: JAMA. 2004 Jun 2;291(21):2581-90
references.pmid: 15173149
references.citation: Eur J Clin Pharmacol. 2004 May;60(3):199-204
references.pmid: 15024533
references.citation: N Engl J Med. 2005 Jun 16;352(24):2515-23
references.pmid: 15958807
references.citation: Arch Gen Psychiatry. 1988 Dec;45(12):1069-77
references.pmid: 2848472
references.citation: Eur Neuropsychopharmacol. 2005 Aug;15(4):357-76
references.pmid: 15961293
references.citation: Health Aff (Millwood). 2003 May-Jun;22(3):122-33
references.pmid: 12757277
references.citation: Acta Psychiatr Scand Suppl. 2004;(420):47-54
references.pmid: 15128387
references.citation: Soz Praventivmed. 2001;46(3):186-94
references.pmid: 11565448
references.citation: Psychol Med. 2004 May;34(4):597-611
references.pmid: 15099415